Pseudohypoparathyroidism Type 1A with Normocalcaemia, due to the Novel C.389A>G Variant of Exon 5 of the Guanine Nucleotide-Binding Protein, α-Stimulating Gene.
GTP-binding protein alpha subunits, Gs
Guanine nucleotides
MAP kinase kinase 1
Pseudohypoparathyroidism
Journal
Journal of bone metabolism
ISSN: 2287-6375
Titre abrégé: J Bone Metab
Pays: Korea (South)
ID NLM: 101599927
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
02
11
2020
accepted:
28
12
2020
entrez:
18
3
2021
pubmed:
19
3
2021
medline:
19
3
2021
Statut:
ppublish
Résumé
Pseudohypoparathyroidism type 1A (PHP1A) is a rare disease caused by molecular defects in the maternally-inherited allele of the guanine nucleotide-binding protein, α-stimulating (GNAS) gene. The GNAS gene encodes the stimulatory G-protein α-subunit that regulates production of the second messenger cyclic adenosine monophosphate. Heterozygous inactivating mutations in these specific loci are responsible for a spectrum of phenotypic characteristics of the disease, including clinical features of the Albright's hereditary osteodystrophy, due to resistance to parathyroid hormone (PTH). We report a case of PHP1A and explore the underlying novel point mutation of the GNAS gene that leads to an atypical PHP1A phenotype. A male patient with a round face, short stature, and brachydactyly accompanied by normocalcaemia and mild PTH resistance consulted at our center. The GNAS encoding region from the patient and both of his parents were amplified and sequenced directly in a sample of peripheral blood leukocytes. A novel c.389A>G point mutation in exon 5 of the GNAS gene, resulting in a p.Tyr130Cys peptidic chain change of the Gsα protein, detected in the proband, in heterozygous state. Sequencing of the GNAS gene from his parents did not reveal the c.389A>G mutation, confirming a de novo proband genotype. The maternal origin of the affected GNAS allele, along with mild PTH resistance, confirmed the PHP1A diagnosis. PHP1A, caused by inactivating GNAS mutations, presents a range of complex clinical phenotypes. The novel c.389A>G GNAS mutation presented in this case expands the spectrum of known PHP1A molecular defects and describes the associated phenotype.
Identifiants
pubmed: 33730787
pii: jbm.2021.28.1.85
doi: 10.11005/jbm.2021.28.1.85
pmc: PMC7973403
doi:
Types de publication
Journal Article
Langues
eng
Pagination
85-89Références
Endocr J. 2008 Mar;55(1):169-73
pubmed: 18250541
J Endocr Soc. 2019 May 20;3(7):1383-1389
pubmed: 31286103
J Pediatr. 2006 Dec;149(6):877-880
pubmed: 17137912
BMC Med Genet. 2018 Jul 30;19(1):132
pubmed: 30060753
Best Pract Res Clin Endocrinol Metab. 2006 Dec;20(4):501-13
pubmed: 17161328
Eur J Endocrinol. 2016 Dec;175(6):P1-P17
pubmed: 27401862
J Clin Endocrinol Metab. 2007 May;92(5):1764-8
pubmed: 17299070
Nat Rev Endocrinol. 2018 Aug;14(8):476-500
pubmed: 29959430
J Endocrinol Invest. 2001 Sep;24(8):642-3
pubmed: 11686549
Endocr Rev. 2001 Oct;22(5):675-705
pubmed: 11588148
Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14794-9
pubmed: 15459318
J Clin Endocrinol Metab. 2016 Oct;101(10):3657-3668
pubmed: 27428667
Clin Endocrinol (Oxf). 2016 Mar;84(3):463-5
pubmed: 26401884
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868